{"pmid":32470207,"title":"Frequency of lupus anticoagulant in Covid-19 patients.","text":["Frequency of lupus anticoagulant in Covid-19 patients.","We have recently published in the Journal of Thrombosis and Haemostasis the presence of lupus anticoagulant (LAC) at high frequency in Covid-19 patients (Harzallah et al.(1) ). Bowles et al.(2) and Helms et al.(3) have confirmed these results in new publications. Tang(4) has reported discordant data. He has found that very few tested covid-19 patients had positive LAC in a small series (n=12). Bowles et al. have found that LAC were positive in 91% of patients (n=34) with high activated partial thromboplastin time (aPTT).","J Thromb Haemost","Harzallah, Ines","Debliquis, Agathe","Drenou, Bernard","32470207"],"abstract":["We have recently published in the Journal of Thrombosis and Haemostasis the presence of lupus anticoagulant (LAC) at high frequency in Covid-19 patients (Harzallah et al.(1) ). Bowles et al.(2) and Helms et al.(3) have confirmed these results in new publications. Tang(4) has reported discordant data. He has found that very few tested covid-19 patients had positive LAC in a small series (n=12). Bowles et al. have found that LAC were positive in 91% of patients (n=34) with high activated partial thromboplastin time (aPTT)."],"journal":"J Thromb Haemost","authors":["Harzallah, Ines","Debliquis, Agathe","Drenou, Bernard"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32470207","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/jth.14937","weight":0,"_version_":1668167110002475009,"score":9.490897,"similar":[{"pmid":32379935,"title":"Response to \"Lupus anticoagulant is frequent in patients with Covid-19\".","text":["Response to \"Lupus anticoagulant is frequent in patients with Covid-19\".","We appreciate the opportunity to respond to the letter from Dr. Ines Harzallah, et al. Antiphospholipid antibody assays including lupus anticoagulant (LAC), anticardiolipin and anti-beta2-glycoprotein I have also been performed in dozens of our patients, however, very few of them got positive results, we don't think that antiphospholipid antibody exists universally in COVID-19 patients. In addition, two of the three reported cases with antiphospholipid antibodies mentioned in the letter [1] also seem to meet the International Society on Haemostasis and Thrombosis (ISTH) criteria of disseminated intravascular coagulation [2], the causality between antiphospholipid antibodies and thrombosis in these cases is still uncertain.","J Thromb Haemost","Tang, Ning","32379935"],"abstract":["We appreciate the opportunity to respond to the letter from Dr. Ines Harzallah, et al. Antiphospholipid antibody assays including lupus anticoagulant (LAC), anticardiolipin and anti-beta2-glycoprotein I have also been performed in dozens of our patients, however, very few of them got positive results, we don't think that antiphospholipid antibody exists universally in COVID-19 patients. In addition, two of the three reported cases with antiphospholipid antibodies mentioned in the letter [1] also seem to meet the International Society on Haemostasis and Thrombosis (ISTH) criteria of disseminated intravascular coagulation [2], the causality between antiphospholipid antibodies and thrombosis in these cases is still uncertain."],"journal":"J Thromb Haemost","authors":["Tang, Ning"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32379935","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/jth.14890","weight":0,"_version_":1666262687570460673,"score":283.57086},{"pmid":32324958,"title":"Lupus anticoagulant is frequent in patients with Covid-19.","text":["Lupus anticoagulant is frequent in patients with Covid-19.","Patients hospitalized for Covid-19 severe infection are more prone to excessive coagulation activation leading to thrombotic events. Tang et al.1 discussed the importance of high D-dimer and Fibrin degradation product level to determine the patient prognostic and the risk of thrombosis. However they did not look at lupus anticoagulant (LAC). Zhang et al. described, three cases of thrombosis associated with antiphospholipid antibodies represented by anticardiolipin (aCL) and anti-beta2-glycoprotein I (abeta2GPI)2. No lupus anticoagulant was detected in any of the patients.","J Thromb Haemost","Harzallah, Ines","Debliquis, Agathe","Drenou, Bernard","32324958"],"abstract":["Patients hospitalized for Covid-19 severe infection are more prone to excessive coagulation activation leading to thrombotic events. Tang et al.1 discussed the importance of high D-dimer and Fibrin degradation product level to determine the patient prognostic and the risk of thrombosis. However they did not look at lupus anticoagulant (LAC). Zhang et al. described, three cases of thrombosis associated with antiphospholipid antibodies represented by anticardiolipin (aCL) and anti-beta2-glycoprotein I (abeta2GPI)2. No lupus anticoagulant was detected in any of the patients."],"journal":"J Thromb Haemost","authors":["Harzallah, Ines","Debliquis, Agathe","Drenou, Bernard"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32324958","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1111/jth.14867","topics":["Treatment"],"weight":1,"_version_":1666138493881942016,"score":261.6555},{"pmid":32379918,"title":"Coagulopathy of COVID-19 and antiphospholipid antibodies.","text":["Coagulopathy of COVID-19 and antiphospholipid antibodies.","Recently in the Journal of Thrombosis and Haemostasis, Harzallah and colleagues report the results of antiphospholipid antibody testing in a series of 56 patients with confirmed or suspected SARS-CoV-2 infection.[1] Twenty-five patients were found to be positive for lupus anticoagulants, while five patients had either anticardiolipin or anti-beta2-glycoprotein I antibodies. The isotypes for the anticardiolipin and anti-beta2-glycoprotein I antibodies were reportedly IgG and IgM, although specific antibody titers and details of which were found in combination with a lupus anticoagulant in three overlap patients were not reported.","J Thromb Haemost","Connell, Nathan T","Battinelli, Elisabeth M","Connors, Jean M","32379918"],"abstract":["Recently in the Journal of Thrombosis and Haemostasis, Harzallah and colleagues report the results of antiphospholipid antibody testing in a series of 56 patients with confirmed or suspected SARS-CoV-2 infection.[1] Twenty-five patients were found to be positive for lupus anticoagulants, while five patients had either anticardiolipin or anti-beta2-glycoprotein I antibodies. The isotypes for the anticardiolipin and anti-beta2-glycoprotein I antibodies were reportedly IgG and IgM, although specific antibody titers and details of which were found in combination with a lupus anticoagulant in three overlap patients were not reported."],"journal":"J Thromb Haemost","authors":["Connell, Nathan T","Battinelli, Elisabeth M","Connors, Jean M"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32379918","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/jth.14893","topics":["Diagnosis"],"weight":1,"_version_":1666262687574654978,"score":154.12144},{"pmid":32294289,"title":"Venous thromboembolism in COVID-19 patients.","text":["Venous thromboembolism in COVID-19 patients.","We read with interest the study published by Tang and coll.(1) in a recent issue of the Journal of Thrombosis and Haemostasis. In this retrospective analysis, conducted at the Tongji Hospital of Wuhan, China, it is reported that heparin treatment reduces mortality in subjects affected by severe COVID-19 who have \"sepsis-induced coagulopathy\". The definition of severe COVID-19 was the presence of at least one of following: respiratory rate >/=30 breaths /min; arterial oxygen saturation </=93% at rest; PaO2/FiO2 </=300 mmHg. The Authors of this study also reported that, among subjects not treated with heparin, mortality raised according with D-dimer levels. Of note, patients that received heparin in this study were mostly treated with enoxaparin, at the thromboprophylactic dose of 40-60 mg/day, for at least 7 days.","J Thromb Haemost","Porfidia, Angelo","Pola, Roberto","32294289"],"abstract":["We read with interest the study published by Tang and coll.(1) in a recent issue of the Journal of Thrombosis and Haemostasis. In this retrospective analysis, conducted at the Tongji Hospital of Wuhan, China, it is reported that heparin treatment reduces mortality in subjects affected by severe COVID-19 who have \"sepsis-induced coagulopathy\". The definition of severe COVID-19 was the presence of at least one of following: respiratory rate >/=30 breaths /min; arterial oxygen saturation </=93% at rest; PaO2/FiO2 </=300 mmHg. The Authors of this study also reported that, among subjects not treated with heparin, mortality raised according with D-dimer levels. Of note, patients that received heparin in this study were mostly treated with enoxaparin, at the thromboprophylactic dose of 40-60 mg/day, for at least 7 days."],"journal":"J Thromb Haemost","authors":["Porfidia, Angelo","Pola, Roberto"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32294289","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jth.14842","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Enoxaparin","Heparin"],"topics":["Treatment"],"weight":1,"_version_":1666138494470193152,"score":85.27729},{"pmid":32329221,"title":"Type and dose of heparin in COVID-19.","text":["Type and dose of heparin in COVID-19.","We thank the authors for their comments and feedback on the ISTH interim guidance. Hyper-coagulability is indeed a significant issue in COVID-19 and the haemostatic system is shifted markedly towards the procoagulant side in these patients. However, we cannot yet be certain that unfractionated heparin (UFH) is better than low molecular weight heparin (LMWH) in this scenario. Although UFH has been used for several years, it does have practical issues, mainly with respect to the need for frequent monitoring using the activated partial thromboplastin times (aPTT).","J Thromb Haemost","Thachil, Jecko","Tang, Ning","Gando, Satoshi","Falanga, Anna","Levi, Marcel","Clark, Cary","Iba, Toshiaki","Cattaneo, Marco","32329221"],"abstract":["We thank the authors for their comments and feedback on the ISTH interim guidance. Hyper-coagulability is indeed a significant issue in COVID-19 and the haemostatic system is shifted markedly towards the procoagulant side in these patients. However, we cannot yet be certain that unfractionated heparin (UFH) is better than low molecular weight heparin (LMWH) in this scenario. Although UFH has been used for several years, it does have practical issues, mainly with respect to the need for frequent monitoring using the activated partial thromboplastin times (aPTT)."],"journal":"J Thromb Haemost","authors":["Thachil, Jecko","Tang, Ning","Gando, Satoshi","Falanga, Anna","Levi, Marcel","Clark, Cary","Iba, Toshiaki","Cattaneo, Marco"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32329221","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1111/jth.14870","locations":["heparin"],"e_drugs":["Heparin, Low-Molecular-Weight","Heparin"],"topics":["Treatment"],"weight":1,"_version_":1666138494688296960,"score":76.19827}]}